[Edaily Reporter Yoo Jin-hee] #Y2Solution is continuing its rapid growth toward doubling its performance this year, having successfully shed the constraints of traditional manufacturing and transformed itself into a high-tech company. Market expectations are rising as Y2Solution is projected to achieve results approaching last year’s annual sales in the first half of this year alone, following more than double the revenue growth year-over-year in the first quarter.

A ‘Quantum Leap’ Driven by the Bioenergy Business... Racing Ahead Despite Geopolitical Crises

According to the securities industry on the 9th, Y2 Solution’s first-half performance this year is projected to reach the level of last year’s annual revenue. If this materializes, analysts predict that Y2 Solution will easily surpass its annual revenue target of 250 billion won for this year. At the heart of this explosive growth lies the bioenergy business, which the company fully entered in the second half of last year. Despite adverse factors such as global geopolitical risks, including war, and supply chain instability, the bioenergy business is maintaining unparalleled growth by riding the global trend of strengthened eco-friendly policies.

Y2 Solution is currently demonstrating strong competitiveness in the distribution of biodiesel feedstocks (basic raw materials). This is due to the company’s distribution of key raw materials for biofuels—such as soybean oil, corn oil, used cooking oil, and animal fats—and its solidified partnerships with leading domestic and international petrochemical manufacturers.

In particular, the European Union’s (EU) Clean Industrial Deal policy and the decision to impose anti-dumping duties of up to 36.4% on Chinese biodiesel have served as significant tailwinds for Y2Solution. This is because Y2Solution, a Korean company, is rapidly filling the void left by Chinese products by leveraging its price competitiveness.

The achievements of the Bioenergy Division go beyond mere revenue growth. This division serves as a stable cash cow, dramatically improving the company’s profit structure. The abundant liquidity secured through this serves as the ammunition that allows Y2Solution to steadily continue investing in future growth engines, such as new drug development and the robotics business.

Unlike the majority of past bio-venture companies, which had to sell promising pipelines at bargain prices due to funding constraints, Y2Solution has established a structure that maximizes its bargaining power based on its own revenue generation capabilities. Analysts note that the company’s investment pipeline for new businesses has become even more robust, with its existing core power supply unit (PSU) business serving as a solid foundation and its bioenergy division providing strong momentum.

In the robotics business, development of an ultra-low-profile autonomous mobile robot (AMR) platform is in full swing, led by the subsidiary HRT Robotics. To address the chronic issue of low-clearance vehicle movement in industrial settings, the company has adopted a 120-millimeter (mm) ultra-low-profile design. Recently, through collaboration with Wizjin, it has been advancing next-generation drive system technology based on axial flux permanent magnet (AFPM) motors and is set to unveil a prototype within the year.

However, Y2Solution’s stock price has been somewhat undervalued due to doubts about the sustainability of its new business and external variables such as the war. Nevertheless, market confidence is gradually recovering as the company is poised to break its all-time earnings record in the second quarter, following its first-quarter performance.

Subsidiary ‘Luxa’s’ dry age-related macular degeneration treatment… Aiming for a revaluation of corporate value to 1 trillion won

In addition to earnings, market experts point to Y2 Solution’s U.S. joint venture, Luxa Biotechnology (eLuxa), as a key factor that could dramatically transform the company’s valuation. Luxa’s cell therapy for dry age-related macular degeneration (AMD), “RPESC-RPE-4W,” is currently considered one of the most closely watched pipelines in the global ophthalmology market.

Although dry age-related macular degeneration (AMD) is ranked among the top three causes of blindness worldwide, there are currently no treatments that fundamentally improve vision. However, interim results from Luxa’s ongoing Phase 1/2a clinical trial have revealed groundbreaking data showing that patients with legally blind vision regained enough vision to perform daily activities after receiving the treatment. Demonstrating an improvement of an average of 21.67 additional letters of vision 12 months after administration, the drug has also received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

With recent large-scale deals by global Big Pharma companies targeting the wet and dry age-related macular degeneration markets, the value of this sector is being reevaluated. Overseas investment firms and the biotech industry predict that if Luxa successfully completes its Phase 1/2a clinical trial in the second half of the year and releases topline data, its corporate value could soar to at least 1 trillion won.

The activities of Dr. Sally Temple, Luxa’s Chief Scientific Officer (CSO), are further fueling these expectations. Dr. Temple recently garnered attention as the keynote speaker at ARVO 2026, the world’s largest ophthalmology conference, where she unveiled an advanced treatment strategy combining stem cells and artificial intelligence (AI).

Luxa’s research team has maximized development efficiency by introducing AI to identify key therapeutic targets through genome-wide association studies and to model interactions between combination drugs. Luxa has also established a system to streamline the production process for retinal pigment epithelium (RPE) progenitor cells, thereby addressing the challenge of mass production—the biggest hurdle in commercializing stem cells.

A representative from Y2Solution emphasized, “If the period up until last year was about laying the foundation for new businesses and improving our corporate structure, this year marks the first year in which those achievements will be reflected in our financial results.” They added, “Based on the stable cash flow secured through our bioenergy business, we will strive to achieve the successful monetization of our dry age-related macular degeneration (AMD) treatment and deliver tangible results in our robotics business, thereby ensuring our corporate value is fairly recognized.”